THE GENERAL ASSEMBLY OF PENNSYLVANIA

HOUSE BILL

INTRODUCED BY QUINN, BAKER, DiGIROLAMO, WATSON, CALTAGIRONE, COHEN, D. COSTA, P. COSTA, DeLUCA, GILLESPIE, GROVE, HORNAMAN, M. K. KELLER, KILLION, MALONEY, MANN, MICCARELLI, MILLARD, MILNE, MURT, PICKETT, ROSS, K. SMITH, STERN, SWANGER, RAPP, MILLER, HARPER, GINGRICH, GEIST, WATERS, NEILSON, MICOZZIE AND FARRY, JUNE 19, 2012

AS AMENDED ON SECOND CONSIDERATION, HOUSE OF REPRESENTATIVES, OCTOBER 2, 2012   

AN ACT

Amending the act of April 14, 1972 (P.L.233, No.64), entitled

"An act relating to the manufacture, sale and possession of

controlled substances, other drugs, devices and cosmetics;

conferring powers on the courts and the secretary and

Department of Health, and a newly created Pennsylvania Drug,

Device and Cosmetic Board; establishing schedules of

controlled substances; providing penalties; requiring

registration of persons engaged in the drug trade and for the

revocation or suspension of certain licenses and

registrations; and repealing an act," further providing for 

definitions and for prohibited acts and penalties; and

providing for ephedrine and pseudoephedrine and electronic

tracking.

The General Assembly of the Commonwealth of Pennsylvania

hereby enacts as follows:

Section 1.  Section 2(b) of the act of April 14, 1972

(P.L.233, No.64), known as The Controlled Substance, Drug,

Device and Cosmetic Act, is amended by adding definitions to

read:

Section 2.  Definitions.--* * *

(b)  As used in this act:

* * *

"National Association of Drug Diversion Investigators

(NADDI)" means a nonprofit organization that facilitates

cooperation between law enforcement, health care professionals,

state regulatory agencies and pharmaceutical manufacturers in

the prevention and investigation of prescription drug diversion.

"National Precursor Log Exchange (NPLEx)" means a real-time

electronic logging system used by pharmacies and law enforcement

to track sales of over-the-counter (OTC) cold and allergy

medications containing precursors to methamphetamine.

* * *

Section 2.  Section 13(a)(40) and (c) of the act, amended or

added November 23, 2010 (P.L.1081, No.107), are amended to read:

Section 13.  Prohibited Acts; Penalties.--(a)  The following

acts and the causing thereof within the Commonwealth are hereby

prohibited:

* * *

(40)  [The sale at retail of any product containing

ephedrine, pseudoephedrine, phenylpropanolamine, or any of their

salts, optical isomers or salts of optical isomers as the sole

active ingredient unless one of the following applies:

(i)  The product is offered for sale behind a counter where

the public is not permitted.

(ii)  The product is offered for sale within a locked cabinet

that is located in an area of the facility involved to which

customers do have direct access.] (Reserved).

* * *

(c)  Any person who violates the provisions of clauses (21),

(22), (24)[, (39) and (40)] and (39) of subsection (a) shall be

guilty of a misdemeanor, and shall, on conviction thereof, be

punished only as follows:

(1)  Upon conviction of the first such offense, he shall be

sentenced to imprisonment not exceeding six months, or to pay a

fine not exceeding ten thousand dollars ($10,000), or both.

(2)  Upon conviction of the second and subsequent offense, he

shall be sentenced to imprisonment not exceeding two years, or

to pay a fine not exceeding twenty-five thousand dollars

($25,000), or both.

* * *

Section 3.  The act is amended by adding a section to read:

Section 13.6.  Ephedrine and Pseudoephedrine; Electronic

Tracking.--(a)  Retailers shall be limited from sales prohibited

<--

from making sales to an individual of, and an individual shall

be limited from purchases of prohibited from purchasing, 

<--

ephedrine or pseudoephedrine base, or their salts, isomers or

salts of isomers in excess of the following amounts:

<--

(1)  3.6 grams of ephedrine or pseudoephedrine base contained

in a product or combination of products per day.

(2)  9 grams of ephedrine or pseudoephedrine base contained

in a product or combination of products per thirty-day period.

(b)  Nonprescription products containing ephedrine or

pseudoephedrine shall be maintained behind the counter or in a

locked case where the customer does not have direct access.

(c)  A retailer shall require any person purchasing a

nonprescription product that contains ephedrine or

pseudoephedrine to present a valid government-issued photo

identification, or other document considered acceptable under

<--

Federal law for this purpose, at the point of sale. The retailer

shall record the following:

(1)  Name and address of the purchaser.

(2)  Name and quantity of product purchased.

(3)  Date and time of purchase.

(4)  Purchaser identification type and number, such as

driver's license state and number, and require the purchaser's

signature in a logbook.

(d)  A retailer shall, before completing a sale under this

section, electronically submit the required information to the

National Precursor Log Exchange (NPLEx) administered by the

National Association of Drug Diversion Investigators (NADDI).

Absent wantonness, recklessness or deliberate misconduct, any

retailer using the electronic sales tracking system in

accordance with this subsection shall not be civilly liable as a

result of any act or omission in carrying out the duties

required by this subsection and shall be immune from liability

to any third party unless the retailer has violated any

provision of this subsection in relation to a claim brought for

such violation.

(e)  If a retailer selling a nonprescription product

containing ephedrine or pseudoephedrine experiences mechanical

or electronic failure of the electronic sales tracking system

and is unable to comply with the electronic sales tracking

requirement, the retailer shall maintain a written log or an

alternative electronic recordkeeping mechanism until such time

as the retailer is able to comply with the electronic sales

tracking requirement. A retailer that does not have Internet

access to the electronic sales tracking system is compliant with

the requirements of this section if the retailer maintains a

written log or an alternative recordkeeping mechanism.

(f)  NADDI shall forward State transaction records in the

NPLEx to the department weekly and provide real-time access to

the NPLEx information through the NPLEx online portal to law

enforcement in this Commonwealth as authorized by the

department.

(g)  The department shall work with NADDI to ensure that

NPLEx shall be capable of generating a stop sale alert, which

shall be a notification that completion of the sale would result

in the seller or purchaser violating the quantity limits set

forth in this section. The seller shall not complete the sale if

the electronic system generates a stop sale alert. The 

department shall work with NADDI to ensure that the system

contains an override function that may be used by a retailer of

ephedrine or pseudoephedrine who has a reasonable fear of

imminent bodily harm if it does not complete a sale. Each

instance in which the override function is used shall be logged

by the system.

(h)  A violation of any provision of this section is a

misdemeanor, punishable by fine only.

(i)  This section does not apply to a person who obtains the

product pursuant to a valid prescription.

(j)  This section shall supersede any other laws or

regulations governing the sales of products containing ephedrine

or pseudoephedrine.

Section 4.  This act shall take effect in 180 270 days.

<--